hema.to GmbH

hema.to GmbH is a Munich-based deeptech company that develops AI-driven software solutions for clinical flow cytometry. The company provides an end-to-end cloud-based platform designed to automate the classification and reporting of cytometry data. By leveraging advanced artificial intelligence, the software aims to remove human-operator variability from manual gating processes, thereby increasing reproducibility, accuracy, and operational efficiency in diagnostic workflows. The platform is designed to be panel-independent, allowing laboratories to streamline their analysis without being locked into specific hardware or standardized operating procedures.

These solutions are intended to assist hematopathologists and laboratories in managing complex diagnostic data, particularly for blood cancers and immune system-related indications. By providing objective, expert-level analysis, hema.to helps clinical teams reduce turnaround times for urgent cases and standardize results across different sites. The company has gained traction in routine clinical settings, with its technology being utilized by various hematology laboratories to support personalized treatment decisions. Founded in 2021, the firm is supported by international investors and maintains a focus on secure, GDPR-compliant, and regulatory-certified workflows to meet the requirements of clinical diagnostic environments.